OTC · Health care

Agentix Corp. (AGTX)

It posted a net loss of $417.5K. At June 30, 2026 it held $38 in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

Watch AGTX in 60 seconds

Price

$0.02

0.00% on the day · September 25, 2026

52-week range $0.01 to $0.06

Market cap

$801.3K

What Agentix Corp. does

Agentix Corp. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker AGTX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2026	n/a	-$445.2K	-$485.6K	-$0.01	n/a
2025	n/a	-$513.3K	-$567K	-$0.01	n/a
2024	n/a	-$744.8K	-$585.2K	-$0.01	n/a
2023	$0	-$1.4M	-$1.4M	n/a	n/a
2022	$1.2K	-$2.6M	-$2.6M	n/a	n/a
2021	$1.2K	-$1.3M	-$1.3M	-$0.04	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 19, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 20, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Agentix Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 10, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS $0.00 versus $0.00.
July 1, 2026
Annual report 10-K · period to March 31, 2026Diluted EPS -$0.01 versus -$0.01.
February 17, 2026
Quarterly report 10-Q · period to December 31, 2025Diluted EPS $0.00 versus $0.00.
November 20, 2025
Quarterly report 10-Q · period to September 30, 2025Diluted EPS $0.00 versus $0.00.
August 22, 2025
Quarterly report 10-Q · period to June 30, 2025Diluted EPS was $0.00.
August 15, 2025
Late quarterly report notice NT 10-Q
July 16, 2025
Annual report 10-K · period to March 31, 2025Diluted EPS -$0.01 versus -$0.01.
July 1, 2025
Late annual report notice NT 10-K
February 18, 2025
Quarterly report 10-Q · period to December 31, 2024Diluted EPS was $0.00.
February 14, 2025
Late quarterly report notice NT 10-Q

Recent insider filings (Forms 3, 4 and 144): 10, the latest on May 22, 2020. Insider transactions on SEC

All filings on SEC EDGAR

Questions about AGTX

What does Agentix Corp. do?

Agentix Corp. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on OTC under the ticker AGTX.

Is Agentix Corp. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $417.5K.

When did Agentix Corp. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026.

Similar companies

AMGN

Amgen Inc

GILD

Gilead Sciences, Inc.

Neurocrine Biosciences Inc

EXEL

Exelixis, Inc.

Compare AGTX with

Compare AGTX with any company

Follow AGTX

Get an email when Agentix Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow AGTX: get an email when it files

Where the numbers come from

Financial figures are the values Agentix Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.